ReviewClinical rheumatology2026
Reprogramming of the lipid metabolism axis in systemic sclerosis: mechanism analysis and therapeutic potential.
Review in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis (SSc), a highly fatal autoimmune disease, is characterized by pathological hallmarks including microvascular damage, immune dysregulation, and progressive fibrosis affecting the skin and multiple organs. Clinically, SSc-related interstitial lung disease and cardiovascular complications represent the primary causes of mortality. Emerging research has highlighted the role of lipid metabolism dysregulation in SSc pathogenesis, with clinically observed abnormal lipid profiles potentially linked to disease progression. Advances in lipidomics have elucidated pathological alterations in specific lipid species and their signaling pathways, offering novel insights into metabolic reprogramming in SSc and identifying potential therapeutic targets. This review synthesizes current evidence on lipid abnormalities in SSc patients, focusing on the interplay between dyslipidemia and three core pathological processes: vascular injury, immune dysfunction, and fibrotic remodeling. Additionally, we briefly analyze the effects of existing drug interventions on the lipid profile of SSc patients, providing a foundation for developing lipid metabolism-targeted therapies to refine clinical management.
Indexed as
Identifiers
42217100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.